Eating behaviour and oxytocin in patients with childhood‐onset craniopharyngioma and different grades of hypothalamic involvement

Daubenbüchel, Anna M.; Özyurt, Jale; Boekhoff, Svenja; Warmuth‐Metz, Monika; Eveslage, Maria; Müller, Hermann L.

doi:10.1111/ijpo.12527

Cited by 20 publications

(21 citation statements)

References 48 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although some patients with HO have significant hyperphagia, it is not a consistent finding ( 1 , 2 , 7 , 8 ). Instead, the energy imbalance in HO is most likely due to reduced energy expenditure without a compensatory decrease in energy intake ( 1 , 7 ).…”

Section: Introductionmentioning

confidence: 90%

Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist

et al. 2022

View full text Add to dashboard Cite

Background/Objectives: Hypothalamic obesity (HO) frequently occurs following suprasellar tumors from a combination of decreased energy expenditure and increased energy intake. Glucagon-like peptide-1 receptor agonist (GLP1RA) therapy is associated with increased satiety and energy expenditure. We hypothesized GLP1RA therapy in patients with HO would cause both lower energy intake and increased energy expenditure. Subjects/Methods: Forty-two patients aged 10–26 years (median 16 years) with HO with suprasellar tumors were randomized to GLP1RA (exenatide extended release once-weekly, ExQW, n=23) or placebo (n=19). Thirty seven (81%) patients completed the 36-week double-blind placebo-controlled trial. Total energy expenditure (TEE) was measured with doubly labeled water, physical activity was assessed with actigraphy, and intake was estimated with ad libitum buffet meal. Results are presented as adjusted mean between-group difference. Results: As compared with treatment with placebo, treatment with ExQW was associated with decreased energy intake during a buffet meal (−1 800 kJ (−430 kcal), 95% CI −3 184 to −418 kJ, p= 0.02). There were no significant differences in physical activity between groups. ExQW (vs. placebo) treatment was associated with a decrease in TEE (−695 kJ/day (−166 kcal/day), 95% CI −1 130 to −264 kJ/day, p< 0.01, adjusted for baseline TEE). The treatment effect was still significant after further adjustment for change in body composition (−372 kJ/day (−89 kcal/day), 95% CI −699 to −42 kJ/day, p= 0.04) or change in leptin (−695 kJ/day (−166 kcal/day), 95% CI −1 130 to −264 kJ/day, p< 0.01). This decrease in TEE occurred despite an increase in lean mass and fat mass (1.7 vs. 1.3 kg lean mass, p= 0.88 and 1.5 vs. 4.6 kg fat mass, p= 0.04, ExQW vs. placebo). Conclusions: Treatment with a GLP1RA was associated with a decrease in food intake but also a decrease in TEE that was disproportionate to change in body composition.

show abstract

Section: Introductionmentioning

confidence: 90%

Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist

et al. 2022

View full text Add to dashboard Cite

show abstract

“…After administration, the CP patients with surgical hypothalamic lesions limited to the anterior hypothalamic areas presented an improvement with regard to emotional identification compared to CP patients with anterior and posterior hypothalamic lesions. Daubenbüchel et al [83,85] analyzed the association between oxytocin saliva concentration and eating behavior in CP Fig. 4.…”

Section: Pharmacological Treatment Of Homentioning

confidence: 99%

The Diagnosis and Treatment of Craniopharyngioma

Müller

2019

Neuroendocrinology

Self Cite

View full text Add to dashboard Cite

Craniopharyngioma (CP) is a rare embryonic malformation of the sellar/parasellar region with a low histological grade. Clinical manifestations are related to hypothalamic/pituitary deficiencies, visual impairment, and increased intracranial pressure. Recent insight into the molecular pathogenesis of CP opens new perspectives on targeted therapy in papillary CP harboring BRAF-V600E mutations. Further research to elucidate pathogenic mechanisms and hopefully prevent hypothalamic involvement of CP is warranted. If the tumor is favorably localized, the therapy of choice is complete resection, with care taken to preserve the optical and hypothalamic functions. In patients with unfavorable tumor localization (i.e., hypothalamic involvement), the recommended therapy is a limited hypothalamus-sparing surgical strategy followed by local irradiation. Surgical treatment strategies should be based on a multidisciplinary approach involving experienced teams. Centralizing the treatment of CP in experienced "centers of excellence" and multicenter-based networks for reference assessments should be considered to assure a high standard of treatment quality. CP recurrence and progression are frequent. Irradiation has proven effective in reducing recurrences and progression. Proton beam therapy, available in a wider range in the near future, will help to avoid radiooncological side effects. Anatomical involvement and/or surgical lesions of posterior hypothalamic areas can result in serious sequelae that compromise quality of life (QoL), such as hypothalamic obesity and psychopathological symptoms. Novel insights into neuropsychological sequelae after CP occurrence should be the basis for the development of therapeutic neuropsychological interventions. CP should be managed as a frequently chronic disease, providing ongoing care of pediatric and adult patients' clinical and QoL consequences by experienced multidisciplinary teams.

show abstract

“…Cook et al ( 85 ) stated that treatment with low-dose intranasal OT resulted in increased desire for socialization and improvement in affection toward family, and the potential of intranasal OT to restore social and behavioral function to pediatric craniopharyngioma survivors should be further explored. Reduced postprandial OT saliva concentrations were observed to be associated with weight problems in childhood-onset craniopharyngioma and adverse eating behavior and symptoms of eating disorders in both childhood-onset craniopharyngioma and controls ( 91 ). The OT supplementation may be a therapeutic option for patients with craniopharyngioma with hypothalamic obesity and/or neurobehavioral disorders caused by particular lesions in the anterior hypothalamus ( 92 ).…”

Section: Pituitary Hormone Deficiencymentioning

confidence: 99%

Endocrine Disorder in Patients With Craniopharyngioma

Zhou

Zhang

2021

Front. Neurol.

View full text Add to dashboard Cite

Craniopharyngioma is an intracranial congenital epithelial tumor growing along the pathway of the embryonic craniopharyngeal tube. The main clinical symptoms of patients with craniopharyngioma include high intracranial pressure, visual field defect, endocrine dysfunction, and hypothalamic dysfunction. At present, the preferred treatment remains the surgical treatment, but the recovery of endocrine and hypothalamic function following surgery is limited. In addition, endocrine disorders often emerge following surgery, which seriously reduces the quality of life of patients after operation. So far, research on craniopharyngioma focuses on ways to ameliorate endocrine dysfunction. This article reviews the latest research progress on pathogenesis, manifestation, significance, and treatment of endocrine disorders in patients with craniopharyngioma.

show abstract

Eating behaviour and oxytocin in patients with childhood‐onset craniopharyngioma and different grades of hypothalamic involvement

Cited by 20 publications

References 48 publications

Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist

Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist

The Diagnosis and Treatment of Craniopharyngioma

Endocrine Disorder in Patients With Craniopharyngioma

Contact Info

Product

Resources

About